Scilex Holding (SCLX) EBT Margin (2022 - 2026)
Scilex Holding (SCLX) posted quarterly EBT Margin of 530.81% for Q1 2026, down 921.0% year-over-year from 64.65% in Q1 2025, and up 44.27% on a QoQ basis from 952.46% in Q4 2025.
Scilex Holding (SCLX) EBT Margin (2022 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported EBT Margin for 5 consecutive years, with 530.81% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin fell 921.0% year-over-year to 530.81%; the TTM figure through Mar 2026 stood at 1161.19% (down 101424.0% YoY), while the FY2025 annual figure was 1234.41%, down 110575.0% from the prior year.
- EBT Margin came in at 530.81% for Q1 2026 at Scilex Holding, up from 952.46% in the prior quarter.
- The five-year high for EBT Margin was 188.89% in Q3 2022, with the low at 2441.47% in Q3 2025.
- Average EBT Margin over 5 years is 397.14%, with a median of 225.41% recorded in 2022.
- Across the five-year window, EBT Margin surged 32078 bps in 2024 and plunged 241107 bps in 2025, its largest moves.
- Year by year, EBT Margin stood at 149.71% in 2022, then dropped by 6 bps to 158.91% in 2023, then jumped by 73 bps to 43.36% in 2024, then plunged by 2097 bps to 952.46% in 2025, then surged by 44 bps to 530.81% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 530.81%, 952.46%, and 2441.47% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 44.70% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 24.89% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 6.93% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 27.21% |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -21.49% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 24.18% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 37.07% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 135.53% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | -530.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -530.81% |
| Dec 31, 2025 | -952.46% |
| Sep 30, 2025 | -2,441.47% |
| Jun 30, 2025 | -444.92% |
| Mar 31, 2025 | -521.60% |
| Dec 31, 2024 | -43.36% |
| Sep 30, 2024 | -30.40% |
| Jun 30, 2024 | -229.58% |
| Mar 31, 2024 | -223.97% |
| Dec 31, 2023 | -158.91% |
| Sep 30, 2023 | -351.18% |
| Jun 30, 2023 | -211.83% |
| Mar 31, 2023 | -290.54% |
| Dec 31, 2022 | -149.71% |
| Sep 30, 2022 | 188.89% |
| Jun 30, 2022 | -225.41% |
| Mar 31, 2022 | -134.17% |